Solid cancers comprise a large number of new cases and deaths from cancer each year
globally. There are a number of strategies for addressing tumors raised from solid organs …

Osteosarcoma is the most common primary bone cancer in children and young adults.
Limited progress has been made in improving the survival outcomes in patients with …

Objective The objective was to review the pharmacology, efficacy, and safety of
atezolizumab (Tecentriq) for the treatment of adult and pediatric patients aged 2 years and …

The pharmacokinetics of monoclonal antibodies is highly variable among patients. Several
factors of variability, referred to as covariates in pharmacokinetic modeling, are known to …

Constant technological advancement enabled the production of therapeutic monoclonal
antibodies (mAbs) and will continue to contribute to their rapid expansion. Compared to …

Master protocols are innovative clinical trial designs that enable new approaches to
analytics and operations, creating value for patients and drug developers. To date, the use …

Purpose To characterize the pharmacokinetics (PK) of zanidatamab including evaluation of
the impact of intrinsic and extrinsic patient factors. To investigate alternative dosing …

Developing medicines for children is now established in legislation in both the United States
and Europe; new drugs require pediatric study or investigation plans as part of their …

Background Increased understanding of how the immune system regulates tumor growth
has innovated the use of immunotherapeutics to treat various cancers. The impact of such …

Introduction: Phase 1b GO30140 and phase 3 IMbrave150 studies evaluated first-line
atezolizumab+ bevacizumab for unresectable hepatocellular carcinoma (HCC). Here, we …